Clinical Impact of β-Lactamase-producing Enterobacteriaceae in Sputum of Cystic Fibrosis Patients

Huda Mussaffi, Naama Fisch Shvalb, Haim Ben-Zvi, Gilat Livni, Meir Mei-Zahav, Dario Prais, Patrick Stafler, Guy Steuer, Hannah Blau*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

This case series describes 18 cystic fibrosis (CF) patients of a 135-patient CF center cohort with extended spectrum β-lactamase-producing Enterobacteriaceae, from 2003 to 2012. Four had chronic infection. Prevalence increased annually from 0 to 6.35%. Risk factors compared with the 2010 CF center cohort included continuous inhaled antibiotics (P = 0.014) and courses of intravenous antibiotics during the year before first isolation (P = 0.009). Hospitalization rates were 1.05/year and 0.47/year preinfection and postinfection, respectively (P = 0.02). Slope of forced expiratory volume at 1 second% predicted remained unchanged during 12 months.

Original languageEnglish
Pages (from-to)216-219
Number of pages4
JournalPediatric Infectious Disease Journal
Volume35
Issue number2
DOIs
StatePublished - 1 Feb 2016

Keywords

  • airway infection
  • cystic fibrosis
  • extended spectrum β-lactamase
  • producing Enterobacteriaceae

Fingerprint

Dive into the research topics of 'Clinical Impact of β-Lactamase-producing Enterobacteriaceae in Sputum of Cystic Fibrosis Patients'. Together they form a unique fingerprint.

Cite this